Bayer bets big as hemophilia competition hots up
This article was originally published in Scrip
Executive Summary
Bayer has announced it is investing €500m in Germany to create new manufacturing capacity for two hemophilia A treatments in its late-stage pipeline. The recombinant Factor VIII products in question are BAY 81-8973 and BAY 94-9027, both of which offer improvements over existing therapies.
You may also be interested in...
Shire Backs Hemophilia Focus With Asset Updates, Irish iPATH Study
Newly enlarged Shire PLC is showcasing its Baxalta component's dynamic hematology portfolio and pipeline at the WFH congress in Orlando, Florida and tells Scrip of its plans for a novel study in Ireland with renowned institutions there using advanced data technology to redefine hemophilia care.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.